
Pharmaceutical Executive
Pharmaceutical Executive PodcastAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 3 minutes
- Latest episode:
About this show
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com (http://PharmExec.com) to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Covers: pharmaceutical industry, drug regulation, pharma business, drug approvals, clinical trials, pharmaceutical dealmaking, obesity drugs, oncology drugs, pharma commercial strategy
Show details and episodes come from the publisher's public feed at audioboom.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast features in-depth interviews with pharmaceutical industry leaders on commercial trends, major conferences and key issues in the sector. Recent episodes cover FDA approvals, Ossium Health's deceased-donor bone marrow bank, Moderna's growth plan and argenx's acquisition of Unnatural Products.
Cosmos
Similar in subject
- BiotechTV - News
Both cover: drug approvals, pharmaceutical industry, clinical trials - On The Pen GLP-1 News
Both cover: drug regulation, clinical trials - The BioCentury Show
Both cover: pharmaceutical dealmaking, clinical trials
Similar shows
Explore more
Episodes
Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic
· 3 min
Not rated yetPharmaceutical Executive Daily: FDA Approves Fayuvi
· 3 min
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Not rated yetPharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
· 3 min
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Not rated yetPharmaceutical Executive Daily: Novo Partners with Anthropic
· 2 min
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
Not rated yetPharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
· 3 min
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Not rated yetPharmaceutical Executive Daily: Novo Nordisk Enters Rebrand
· 3 min
Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.
Not rated yetPharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy
· 2 min
Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.
Not rated yet- Not rated yet
340B Under Pressure: Inside Pharma's Push for Greater Clarity
· 33 min
In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to examine the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and legal challenges are shaping manufacturers’ response. Mendelsohn explains drugmaker concerns about overlapping discounts, the gaps in claims visibility that make them difficult to identify and the push to verify dispensing before paying a 340B rebate (all three at the heart of industry revenue leakage issues). Throughout the conversation, Mendelsohn considers what it will take to bring greater accountability and predictability to the program while preserving its underlying purpose. 00:53 - The evolution of 340B 03:39 - Understanding program's growth and impact 07:27 - Manufacturer challenges/complexities in compliance 10:43 - 340B's twisting path: Rebate pilots and more 15:44 - Pharma as key stakeholder 18:25 - Claims collection hurdles 20:56 - Lilly and industry strategy shifts 23:19 - Assessing the litigation landscape 25:37 - 340B's role in pricing pie, GTN management 29:20 - Fueling future debate? The two drivers
Not rated yetPharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B
· 2 min
Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manufacturing flexibility.
Not rated yet